AnteoTechAnteoTechAnteoTechAnteoTech
  • Home
  • About
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • ADVISORY BOARDS
  • Life Science
    • ANTEOBIND
      • ANTEOBIND PUBLICATIONS
    • PRODUCTS
    • CONTRACT SERVICES
    • CASE STUDIES
    • WEBINARS
  • Energy
    • WEBINARS
  • EuGeni
  • Newsroom
  • Investors
    • 2021 ANNUAL GENERAL MEETING
    • ASX ANNOUNCEMENTS
    • CORPORATE GOVERNANCE & COMPANY POLICY
    • VIEW ON ASX
  • Customer Login
  • Contact

AnteoTech renews AnteoBind contract with Ellume

    Home Uncategorized AnteoTech renews AnteoBind contract with Ellume
    NextPrevious

    AnteoTech renews AnteoBind contract with Ellume

    By AnteoTech | Uncategorized | 0 comment | 25 November, 2021 |

    AnteoTech is pleased to advise that it has renewed its contract with leading healthcare diagnostic partner Ellume Ltd. (“Ellume”) for the supply of AnteoBind to be used in Ellume’s range of tests.

    Ellume is an Australia-based diagnostics company that develops, manufactures and commercialises high-performance connected products for health professionals and consumers. Most recently, Ellume became the first over-the-counter fully at-home diagnostic test for COVID-19 to be granted authorisation from the US Food and Drug Administration. This test utilises AnteoTech’s unique AnteoBind technology.

    AnteoTech and Ellume have been in partnership since 2016, and this contract renewal highlights the strong relationship between the two companies. The terms of the contract are commercial-in-confidence and reflect the commercial positions of both companies having undergone significant transformation over the past five years.

    AnteoTech CEO Derek Thomson said, “We are very pleased to have renewed our sales contract with Ellume. Ellume has been a longstanding customer and have used our AnteoBind technology to great effect. We look forward to supporting Ellume to achieve their ambition of a large volume of test sales in the US market in 2022 and beyond.”

    No tags.

    AnteoTech

    More posts by AnteoTech

    Related Post

    • Exxe Appointed as Italian Distributor

      By AnteoTech | 0 comment

      AnteoTech welcomes EXXE S.r.l (EXXE) to the EuGeni family. Based in Milan, Italy, EXXE is AnteoTech’s fifth European distributor for the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT). We are excited atRead more

    • Spanish and Portuguese Distribution Agreement for EuGeni

      By AnteoTech | 0 comment

      AnteoTech broadens European market exposure, securing a Spanish and Portuguese Distribution Agreement for EuGeni AnteoTech is pleased to welcome another newly appointed distributor to the EuGeni family. Most recently, AnteoTech has appointed Vitro Master DiagnosticaRead more

    • Australian-made RATs await TGA approval amid rapid antigen test shortage

      By AnteoTech | 0 comment

      Australian-made RATs await TGA approval amid rapid antigen test shortage  Read more

    NextPrevious

    Recent Posts

    • Australian-made RATs await TGA approval amid rapid antigen test shortage
    • AnteoTech renews AnteoBind contract with Ellume
    • Spanish and Portuguese Distribution Agreement for EuGeni
    • Exxe Appointed as Italian Distributor

    Recent Comments

      Quick Links

      • About
      • Life Science
      • Energy
      • Investors
      • Customer Login

      Investors

      • ASX Announcements
      • Corporate Governance & Company Policy
      • Financial Reporting
      • Share Price Information

      Contact Us

      If you have any general questions about our products or technology, contact customer support on (07) 3219 0085 or email contact@anteotech.com. For all technical support, please email support@anteotech.com.

      For all investor-related queries please email investors@anteotech.com.

      Copyright © AnteoTech 2021. All rights reserved. AnteoCoat/AnteoBind are trademarks of the AnteoTech group of companies. All other trademarks referenced are owned by their respective companies.
      Website by Start Digital
      • Home
      • About
        • MANAGEMENT TEAM
        • BOARD OF DIRECTORS
        • ADVISORY BOARDS
      • Life Science
        • ANTEOBIND
          • ANTEOBIND PUBLICATIONS
        • PRODUCTS
        • CONTRACT SERVICES
        • CASE STUDIES
        • WEBINARS
      • Energy
        • WEBINARS
      • EuGeni
      • Newsroom
      • Investors
        • 2021 ANNUAL GENERAL MEETING
        • ASX ANNOUNCEMENTS
        • CORPORATE GOVERNANCE & COMPANY POLICY
        • VIEW ON ASX
      • Customer Login
      • Contact
      AnteoTech